Abstract：
Assessing treatment efficacy for brain tumours has evolved since its inception with the introduction of MacDonald\'s criteria, which pioneered the utility of imaging to determine an objective and quantifiable response to treatment. This criterion failed to distinguish pseudo response or progression from progression and did not account for non-enhancing disease therefore; the response assessment in neuro-oncology (RANO) working group was established to account for these limitations. Since, its commencement it has worked to determine response assessment for multiple tumours. As paediatric tumours exhibit heterogeneous and variable-enhancing characteristics, the response assessment in paediatric neuro-oncology (RAPNO) working group was formed to create separate criteria. Six response criteria have been published to date, and the article summarizes them.
摘要：
评估脑肿瘤的治疗效果从一开始就随着麦克唐纳标准的引入而发展，它开创了成像技术的应用，以确定客观和可量化的治疗反应。该标准未能将假性反应或进展与进展区分开来，因此没有考虑到非增强疾病；建立了神经肿瘤学（RANO）工作组的反应评估来解决这些局限性。因为,它开始致力于确定多个肿瘤的反应评估。由于儿科肿瘤表现出异质性和可变增强特征，儿科神经肿瘤学(RAPNO)工作组的反应评估是为了创建单独的标准.迄今已公布六项回应标准,文章总结了它们。
